Table 1.
Clinical Data Available for the 13 Patients Analyzed
| Case No. | Age (years) | Race | Tumor grade | Tumor size (cm) | Lymph nodes (No. pos./total No.) | Tumor stage | ER status | PR status | HER2 IHC study | G/P/AB | DCIS component |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade | Histologic features | |||||||||||
| 1 | 50.0 | Hispanic | 3 | 1.2 | 2/9 | IIIC | 0 | 0 | 1+ | G4P3AB1 | Intermediate high | Cribriform |
| 2 | 47.3 | White | 1 | 0.9 | 0/20 | IA | 75 | 85 | ND | G3P3AB0 | Intermediate | Cribriform-solid |
| 3 | 73.9 | White | 3 | 3.5 | 2/17 | IIB | 75 | 100 | ND | G2P2AB0 | High | Cribriform-solid |
| 4 | 53.0 | White | 1 | 1.3 | 0/1 | IA | 90 | 100 | 1+ | G1P1AB0 | Intermediate | Cribriform-solid |
| 5 | 62.7 | White | 2 | 3.6 | 0/9 | IIA | 100 | 95 | 2+ | G5P3AB2 | Intermediate | Cribriform-solid |
| 6 | 33.3 | White | 2 | 4.5 | 3/13 | IIB | 90 | 40 | 1+ | G4P3AB1 | Intermediate | Cribriform-solid |
| 7 | 56.0 | White | 3 | 0.6 | 0/37 | IA | 0 | 0 | 0 | G0P0AB0 | High | Cribriform-solid |
| 8 | 59.7 | White | 2 | 1.8 | 1/27 | IIA | <5 | 95 | 0 | G4P2AB2 | Intermediate | Cribriform-solid |
| 9⁎ | 66.1 | African American | 2 | 1.9 | 2/20 | IV | 100 | 50 | 2+ | G2P0AB2 | Intermediate | Cribriform-comedo |
| 10 | 42.8 | Hispanic | 3 | 1.3 | 0/9 | IA | 0 | 0 | 0 | G3P0AB3 | High | Cribriform-solid |
| 11 | 49.6 | Asian | 3 | 2.7 | 0/2 | IIA | 90 | 80 | 3+ | G2P2AB0 | High | Cribriform-solid |
| 12 | 37.0 | White | 2 | 0.8 | 0/2 | IA | 0 | 0 | 3+ | G2P2AB0 | High | Cribriform-solid |
| 13 | 37.8 | White | 3 | 1.8 | 8/14 | IIIA | 95 | 90 | 2+ | Missing | High | Cribriform |
ER, estrogen receptor (>0 is a positive test result); G/P/AB, gravida/para/abortus; IHC, immunohistochemical; ND, not determined; PR, progesterone receptor (>0 is a positive test result).
⁎
Case 9 was the only case with distant metastasis.